Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

BACKGROUND Clinicians who treat patients with Clostridium difficile-associated diarrhea (CDAD) in Quebec, Canada, have noted an apparent increase in the proportion of patients who experience relapse. METHODS To determine whether there was an increase in the frequency of treatment failure and of recurrence of CDAD after treatment, we reviewed data on cases that had been diagnosed in a hospital in the province of Quebec during the period 1991-2004. The frequency of recurrences within 60 days after the initial diagnosis was measured using Kaplan-Meier analysis, and Cox regression was used for multivariate analysis. RESULTS Among patients who had initially been treated with metronidazole, the proportion whose regimens were switched to vancomycin or for whom vancomycin was added because of a disappointing response did not vary between 1991 and 2002 (66 [9.6%] of 688 patients overall) but more than doubled in 2003-2004 (112 [25.7%] of 435; P < .001). Among 845 patients treated with metronidazole only, the 60-day probability of recurrence increased dramatically in 2003-2004 (47.2%), compared with 1991-2002 (20.8%; P < .001). During 1991-2002, the probabilities of recurrence were 20.0%, 13.8%, and 28.9% among individuals aged 0-17, 18-64, and > or = 65 years, respectively; during 2003-2004, the probabilities were 25.0%, 27.1%, and 58.4%, respectively. CONCLUSION In 2003-2004, there was an increase in the proportion of patients with CDAD believed, by their attending physicians, to have experienced metronidazole treatment failure, as well as an increase in the frequency of post-metronidazole therapy recurrences, especially among elderly persons.

[1]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[2]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[3]  J. Bartlett.  Antibiotic associated diarrhea. , 2002, Delaware medical journal.

[4]  B. Greene,et al.  12 MONTH FOLLOW-UP OF MEBENDAZOLE THERAPY FOR ONCHOCERCIASIS , 1981, The Lancet.

[5]  R. N. Brogden,et al.  Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. , 1982, Drugs.

[6]  C. Nord.  Microbiological properties of tinidazole: spectrum, activity and ecological considerations. , 1982, The Journal of antimicrobial chemotherapy.

[7]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[8]  J. Silva.  Antibiotic-associated colitis. , 1984, The Western journal of medicine.

[9]  D. Gordon,et al.  Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. , 1985, Gastroenterology.

[10]  R. Bolton,et al.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. , 1986, Gut.

[11]  M. Dudley,et al.  Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. , 1986, Archives of internal medicine.

[12]  L. Jokipii,et al.  Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius , 1987, Antimicrobial Agents and Chemotherapy.

[13]  J. Bartlett.  Clostridium difficile: clinical considerations. , 1990, Reviews of infectious diseases.

[14]  R. Spencer,et al.  Clostridium difficile infection: responses, relapses and re-infections. , 1992, The Journal of hospital infection.

[15]  D. Gerding,et al.  Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. , 1994 .

[16]  C. Surawicz,et al.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.

[17]  D. Gerding,et al.  Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991 , 1994, Infection Control &#x0026; Hospital Epidemiology.

[18]  Elaine Larson,et al.  Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  W. Graninger,et al.  Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Fekety.  Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. , 1997, The American journal of gastroenterology.

[21]  D. Gerding,et al.  Clostridium difficile--associated diarrhea. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  L. Mcfarland,et al.  Epidemiology, Risk Factors and Treatments for Antibiotic-Associated Diarrhea , 1998, Digestive Diseases.

[23]  C. Surawicz,et al.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Rolfe,et al.  In Vitro and In Vivo Activities of Nitazoxanide against Clostridium difficile , 2000, Antimicrobial Agents and Chemotherapy.

[25]  C. Kelly,et al.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.

[26]  D. Pardi,et al.  Clostridium difficile-associated diarrhea and colitis. , 2001, Mayo Clinic proceedings.

[27]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[28]  E. Goldstein,et al.  In Vitro Activities of Ramoplanin, Teicoplanin, Vancomycin, Linezolid, Bacitracin, and Four Other Antimicrobials against Intestinal Anaerobic Bacteria , 2003, Antimicrobial Agents and Chemotherapy.

[29]  E. Goldstein,et al.  In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[30]  S. Poutanen,et al.  Clostridium difficile-associated diarrhea in adults , 2004, Canadian Medical Association Journal.

[31]  B. Sibbald,et al.  Hospitals battling outbreaks of C. difficile , 2004, Canadian Medical Association Journal.

[32]  M. Warnick,et al.  Evaluation of Perinatal Care Management Programs: An Integrated Review , 2004, Care Management Journals.

[33]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[34]  L. Eggertson.  C. difficile: by the numbers , 2004, Canadian Medical Association Journal.

[35]  Robert Feketv.  Guidelines for the Diagnosis and Management of Clostridium dfficile-Associated Diarrhea and Colitis , 2005 .